Asthma in Adults Flashcards
What is reversible airway obstruction?
In asthma there is reversible airway obstruction that typically responds to bronchodilators such as salbutamol.
What are the typical triggers of asthma?
Infection Symtoms worse at night time or early morning Exercise Animals Cold/damp Dust Strong emotions
Signs of asthma
Tachypnoea
Hyperinflated chest
Hyper-resonance on chest percussion
Decreased air entry (sign of severe illness: silent chest)
Wheeze on auscultation
Signs of a severe asthmatic attack:
Inability to speak in complete sentences, respiratory rate >25, peak flow 33-50% predicted
Signs of a severe asthmatic attack:
Inability to speak in complete sentences, respiratory rate >25, peak flow 33-50% predicted
Signs of a life-threatening attack
Silent chest, confusion, bradycardia, cyanosis, exhaustion
Investigations in chronic asthma
The following investigations and their associated results point to a diagnosis of asthma.
Peak flow: variability >20%
Fractional exhaled nitric oxide (FeNO): >40 ppb in adults or >35 ppb in children
Spirometry: FEV1/FVC <0.7 (obstructive spirometry)
Non-pharma management of chronic asthma
Smoking cessation
Avoidance of precipitating factors (eg. known allergens)
Review inhaler technique
Pharma management of chronic asthma - BTS guideline
- Add short-acting beta 2 agonist inhaler (e.g. salbutamol) as required for infrequent wheezy episodes.
- Add a regular low dose corticosteroid inhaler.
- Add LABA inhaler (e.g. salmeterol). Continue the LABA only if the patient has a good response.
- Consider a trial of an oral leukotriene receptor antagonist (i.e. montelukast), oral beta 2 agonist (i.e. oral salbutamol), oral theophylline or an inhaled LAMA (i.e. tiotropium).
- Titrate inhaled corticosteroid up to “high dose”. Combine additional treatments from step 4. Refer to specialist.
- Add oral steroids at the lowest dose possible to achieve good control.
Pharma management of chronic asthma - NICE
- Add short-acting beta 2 agonist inhaler (e.g. salbutamol) as required for infrequent wheezy episodes.
- Add a regular low dose inhaled corticosteroid. (beclometasone)
- Add an oral leukotriene receptor antagonist (i.e. montelukast).
- Add LABA inhaler (e.g. salmeterol). Continue the LABA only if the patient has a good response.
- Consider changing to a maintenance and reliever therapy (MART) regime.
- Increase the inhaled corticosteroid to a “moderate dose”.
- Consider increasing the inhaled corticosteroid dose to “high dose” or oral theophylline or an inhaled LAMA (e.g. tiotropium).
- Refer to a specialist.
Describe the following in relations to long term asthma management:
Short acting 2 beta adrenergic receptor agonist
For example salbutamol.
These work quickly but the effect only lasts for an hour or two. Adrenalin acts on the smooth muscles of the airways to cause relaxation.
This results in dilatation of the bronchioles and improves the bronchoconstriction present in asthma.
They are used as “reliever” or “rescue” medication during acute exacerbations of asthma when the airways are constricting.
Describe the following in relations to long term asthma management:
Inhaled Corticosteroids (ICS)
Inhaled corticosteroids (ICS), for example beclometasone. These reduce the inflammation and reactivity of the airways.
These are used as “maintenance” or “preventer” medications and are taken regularly even when well.
Describe the following in relations to long term asthma management:
LABA
Long-acting beta 2 agonists (LABA), for example salmeterol. These work in the same way as short acting beta 2 agonists but have a much longer action.
Describe the following in relations to long term asthma management:
LAMA
Long-acting muscarinic antagonists (LAMA), for example tiotropium. These block the acetylcholine receptors. Acetylecholine receptors are stimulated by the parasympathetic nervous system and cause contraction of the bronchial smooth muscles. Blocking these receptors leads to bronchodilation.
Describe the following in relations to long term asthma management:
Leukotriene receptor antagonists
Leukotriene receptor antagonists, for example montelukast. Leukotrienes are produced by the immune system and cause inflammation, bronchoconstriction and mucus secretion in the airways. Leukotriene receptor antagonists work by blocking the effects of leukotrienes.